Please Wait
Applying Filters...
menu
    • menu
    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Koate DVI

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 5Advate

    02 5Kogenate/Kovaltry/ Jivi

    03 2Recombinate

    04 6Refacto AF/Xyntha

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    APGA Annual Conference
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2019 Revenue in Millions : 1,443

    2018 Revenue in Millions : 0

    Growth (%) : N/A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2019 Revenue in Millions : 426

    2018 Revenue in Millions : 514

    Growth (%) : -17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    APGA Annual Conference
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2020 Revenue in Millions : 1,029

    2019 Revenue in Millions : 1,067

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    APGA Annual Conference
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2021 Revenue in Millions : 906

    2020 Revenue in Millions : 1,029

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    APGA Annual Conference
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 1,253

    2019 Revenue in Millions : 1,473

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2020 Revenue in Millions : 370

    2019 Revenue in Millions : 426

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    APGA Annual Conference
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 1,019

    2020 Revenue in Millions : 1,201

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Refacto AF/Xyntha

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Refacto AF/Xyntha

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pfizer Inc.

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Rare Disorders

    Currency : USD

    2021 Revenue in Millions : 304

    2020 Revenue in Millions : 370

    Growth (%) : -18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Kogenate/Kovaltry/ Jivi

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Kogenate/Kovaltry/ Jivi

    Germany
    arrow
    APGA Annual Conference
    Not Confirmed

    Bayer

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 889

    2021 Revenue in Millions : 906

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Advate

    Antihemophilic Factor (Recombinant)

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Advate

    Japan
    arrow
    APGA Annual Conference
    Not Confirmed

    Takeda

    Antihemophilic Factor (Recombinant)

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 935

    2021 Revenue in Millions : 1,019

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF